<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4C34BF72-26A2-4B0F-987E-5629EFE7B7ED"><gtr:id>4C34BF72-26A2-4B0F-987E-5629EFE7B7ED</gtr:id><gtr:name>Chronos Therapeutics Limited</gtr:name><gtr:address><gtr:line1>Frieze Farm
Woodstock Road</gtr:line1><gtr:city>OXFORD</gtr:city><gtr:postCode>OX2 8JX</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4C34BF72-26A2-4B0F-987E-5629EFE7B7ED" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>4C34BF72-26A2-4B0F-987E-5629EFE7B7ED</gtr:id><gtr:name>Chronos Therapeutics Limited</gtr:name><gtr:address><gtr:line1>Frieze Farm
Woodstock Road</gtr:line1><gtr:city>OXFORD</gtr:city><gtr:postCode>OX2 8JX</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>385438.0</gtr:offerGrant><gtr:projectCost>642396.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>214158.0</gtr:offerGrant><gtr:projectCost>214158.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A83ED21B-4C63-408E-93D5-4DDC468530B7"><gtr:id>A83ED21B-4C63-408E-93D5-4DDC468530B7</gtr:id><gtr:firstName>Julia</gtr:firstName><gtr:surname>Sherriff</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=102518"><gtr:id>76A8FD9D-A1A4-4AE7-984D-CA2493A9AEDA</gtr:id><gtr:title>An integrated non-vertebrate drug discovery platform for neurodegenerative disease</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>102518</gtr:grantReference><gtr:abstractText>With a rapidly increasing ageing population, age-related health problems (including neurological disorders such

as Alzheimer?s disease and Parkinson?s disease) are presenting a challenge to, and burden on existing health

care provision. Yet whilst such diseases represent a growing therapeutic need, their treatment is hampered

both by the cost and time commitment to bring new medicines to market. Currently, two major reasons for

failure of new drugs are complications associated with negative side-effects and the ethical and cost issues

associated with experimentation in non-human vertebrates. Our aim is to develop a robust screening platform

in a worm model of neurodegenerative disease. The screening pipeline will make it possible to test drugs for

effectiveness against symptoms of neurodegenerative disease and also establish early on whether the same

drugs have toxic effects; this will help to reduce failure or ?attrition? of drugs at later stages of testing.

Consequently, we anticipate that those drugs that do go through to trial in human subjects will offer the best

likelihood of treatment success without adverse side-effects.</gtr:abstractText><gtr:fund><gtr:end>2019-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2016-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>599596</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">102518</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>